Table 3.
Results of line probe assay for second-line drugs among patients with MDR-TB.
Resistance mutations |
Gene region | ||||
---|---|---|---|---|---|
Not detectable |
Detectable |
||||
N | % | n | % | ||
Fluoroquinolones | 21 | 84.0 | 4 | 16.0 |
gyrA-D94G: 2; gyrA-S91P: 1 gyrB-N538D: 1 |
Am/CM/VIO | 25 | 100.0 | – | – | – |
KN (low level) | 24 | 96.0 | 1 | 4.0 | – |
KN, kanamycin; Am, amikacin; CM, capreomycin; VIO, viomicin.